[
    [
        {
            "time": "2018-01-02",
            "original_text": "Top 5 Biotech Stocks for 2018",
            "features": {
                "keywords": [
                    "Biotech",
                    "Stocks",
                    "2018"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Top 5 Biotech Stocks for 2018",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie",
            "features": {
                "keywords": [
                    "Boeing",
                    "Ford",
                    "American Airlines",
                    "JetBlue",
                    "Pfizer",
                    "Comcast",
                    "Alphabet",
                    "Nvidia",
                    "AbbVie"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "aerospace",
                    "automotive",
                    "airlines",
                    "pharmaceuticals",
                    "technology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2018",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Ex-Dividend",
                    "Date",
                    "July 12, 2018"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2018",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "AbbVie's stock falls after lymphoma treatment trial data disappoints",
            "features": {
                "keywords": [
                    "AbbVie",
                    "stock",
                    "falls",
                    "lymphoma",
                    "treatment",
                    "trial",
                    "data",
                    "disappoints"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie's stock falls after lymphoma treatment trial data disappoints",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Phase 3",
                    "Study",
                    "Ibrutinib",
                    "IMBRUVICA®",
                    "Blood Cancer",
                    "DLBCL"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "Ex-Dividend Alert: AbbVie Has Raised its Dividend By 140% Since 2013; Will Trade Ex-Dividend on July 12, 2018",
            "features": {
                "keywords": [
                    "Ex-Dividend",
                    "Alert",
                    "AbbVie",
                    "Dividend",
                    "Raised",
                    "140%",
                    "Since 2013",
                    "Trade",
                    "July 12, 2018"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Ex-Dividend Alert: AbbVie Has Raised its Dividend By 140% Since 2013; Will Trade Ex-Dividend on July 12, 2018",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "AbbVie Updates On Phase 3 Study Of Ibrutinib In Blood Cancer DLBCL",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Updates",
                    "Phase 3",
                    "Study",
                    "Ibrutinib",
                    "Blood Cancer",
                    "DLBCL"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Updates On Phase 3 Study Of Ibrutinib In Blood Cancer DLBCL",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]